FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971019453> ?p ?o ?g. }

• W2971019453 endingPage "1180" @default.
• W2971019453 startingPage "1169" @default.
• W2971019453 abstract "Background Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, pinteraction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, pinteraction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk. Funding AstraZeneca. Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, pinteraction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, pinteraction=0·012. Benefit was present irrespective of time from most recent PCI. In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk." @default.
• W2971019453 created "2019-09-05" @default.
• W2971019453 creator A5000045667 @default.
• W2971019453 creator A5000125348 @default.
• W2971019453 creator A5000200390 @default.
• W2971019453 creator A5000265282 @default.
• W2971019453 creator A5000291054 @default.
• W2971019453 creator A5000305089 @default.
• W2971019453 creator A5000353692 @default.
• W2971019453 creator A5000380712 @default.
• W2971019453 creator A5000404555 @default.
• W2971019453 creator A5000417125 @default.
• W2971019453 creator A5000559462 @default.
• W2971019453 creator A5000570214 @default.
• W2971019453 creator A5000744614 @default.
• W2971019453 creator A5000882328 @default.
• W2971019453 creator A5000882502 @default.
• W2971019453 creator A5001059361 @default.
• W2971019453 creator A5001136625 @default.
• W2971019453 creator A5001170166 @default.
• W2971019453 creator A5001269440 @default.
• W2971019453 creator A5001345443 @default.
• W2971019453 creator A5001353044 @default.
• W2971019453 creator A5001495172 @default.
• W2971019453 creator A5001576040 @default.
• W2971019453 creator A5001579932 @default.
• W2971019453 creator A5001657828 @default.
• W2971019453 creator A5001696420 @default.
• W2971019453 creator A5001791742 @default.
• W2971019453 creator A5001947120 @default.
• W2971019453 creator A5001979186 @default.
• W2971019453 creator A5002112062 @default.
• W2971019453 creator A5002192806 @default.
• W2971019453 creator A5002270615 @default.
• W2971019453 creator A5002392487 @default.
• W2971019453 creator A5002600607 @default.
• W2971019453 creator A5002705345 @default.
• W2971019453 creator A5002828704 @default.
• W2971019453 creator A5002865126 @default.
• W2971019453 creator A5002898257 @default.
• W2971019453 creator A5003004299 @default.
• W2971019453 creator A5003029676 @default.
• W2971019453 creator A5003038620 @default.
• W2971019453 creator A5003174401 @default.
• W2971019453 creator A5003260407 @default.
• W2971019453 creator A5003374063 @default.
• W2971019453 creator A5003424406 @default.
• W2971019453 creator A5003575693 @default.
• W2971019453 creator A5003622250 @default.
• W2971019453 creator A5003622508 @default.
• W2971019453 creator A5003687230 @default.
• W2971019453 creator A5003802196 @default.
• W2971019453 creator A5003826256 @default.
• W2971019453 creator A5003912538 @default.
• W2971019453 creator A5004035226 @default.
• W2971019453 creator A5004108666 @default.
• W2971019453 creator A5004282546 @default.
• W2971019453 creator A5004290332 @default.
• W2971019453 creator A5004396551 @default.
• W2971019453 creator A5004463542 @default.
• W2971019453 creator A5004522347 @default.
• W2971019453 creator A5004588892 @default.
• W2971019453 creator A5004645448 @default.
• W2971019453 creator A5004716871 @default.
• W2971019453 creator A5004812723 @default.
• W2971019453 creator A5004934159 @default.
• W2971019453 creator A5004966069 @default.
• W2971019453 creator A5004991147 @default.
• W2971019453 creator A5004991173 @default.
• W2971019453 creator A5005014227 @default.
• W2971019453 creator A5005451657 @default.
• W2971019453 creator A5005467408 @default.
• W2971019453 creator A5005598482 @default.
• W2971019453 creator A5005603440 @default.
• W2971019453 creator A5005636085 @default.
• W2971019453 creator A5005829936 @default.
• W2971019453 creator A5005876557 @default.
• W2971019453 creator A5005886200 @default.
• W2971019453 creator A5006121842 @default.
• W2971019453 creator A5006175809 @default.
• W2971019453 creator A5006184249 @default.
• W2971019453 creator A5006419203 @default.
• W2971019453 creator A5006551829 @default.
• W2971019453 creator A5006592671 @default.
• W2971019453 creator A5006598929 @default.
• W2971019453 creator A5006641323 @default.
• W2971019453 creator A5006842721 @default.
• W2971019453 creator A5006851304 @default.
• W2971019453 creator A5006855822 @default.
• W2971019453 creator A5006929907 @default.
• W2971019453 creator A5007047517 @default.
• W2971019453 creator A5007179300 @default.
• W2971019453 creator A5007268785 @default.
• W2971019453 creator A5007333141 @default.
• W2971019453 creator A5007389891 @default.
• W2971019453 creator A5007407303 @default.
• W2971019453 creator A5007681234 @default.
• W2971019453 creator A5007737202 @default.

• next